New research disproves belief that group psychotherapy extends lives of Cancer patients

Newswise — Previously-published research has given credence to the notion that psychotherapy extends the lives of people with cancer. In fact, one in four cancer patients believe that science supports the idea that participating in group therapy will extend their lives. However, in a paper appearing in the May issue of the Psychological Bulletin, researchers at the University of Pennsylvania School of Medicine concluded – after an extensive research review – that there is no compelling evidence linking psychotherapy or support groups with survival among cancer patients.

“We all wish that psychotherapy could prolong life, because it appeals so strongly to firmly-rooted notions that a person should be able to control their destiny,” says lead author, James C. Coyne, PhD, Co-Leader, Cancer Control and Outcomes Program, Abramson Cancer Center and Professor of Psychology in Psychiatry at Penn. “We have a special responsibility to cancer patients to clarify that the reasonable goal of psychotherapy and support groups is to improve their quality of life, not extend it.”

Two studies in particular – Spiegel et al., 1989 and Fawzy et al., 1993 – have been widely interpreted as providing early support for the idea that psychotherapy promotes survival among cancer patients. However, the authors report that the studies had numerous methodological and analytical flaws, including the fact that they were not designed to test the hypothesis that psychotherapy extends the lives of cancer patients. The study investigators had redefined the purpose of their studies after looking at their data – a practice that is generally not acceptable in biomedicine and that often leads to claims that will not be validated in subsequent studies.

Coyne notes, “If these studies had been testing medications, rather than psychotherapy, no one would have paid much attention to the redefined outcome of improved survival, and leading medical journals would probably not have accepted the papers, given their other flaws.”

In the years following these studies, additional studies have been conducted to test for the effect of psychotherapy extending the lives of cancer patients, but none have demonstrated a survival benefit that could logically be attributed to psychotherapy. In biomedicine, a large-scale trial would not be considered warranted for cases in which a hypothesis was interesting but improbable given the available data. Therefore, the authors conclude that there is not enough basis to justify investing additional funding for research in this area.

Additional authors of this research review are Steven C. Palmer, PhD, Abramson Cancer Center of the University of Pennsylvania and Department of Psychiatry; and Michael Stefanek, PhD, American Cancer Society.

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.